Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Feb;20(2):589-592.
doi: 10.1111/ajt.15579. Epub 2019 Sep 11.

The use of ruxolitinib for acute graft-versus-host disease developing after solid organ transplantation

Miriam T Jacobs  1 , Marissa Olson  1 , Bruna Pellini Ferreira  1 , Ramon Jin  1 , Ramsey Hachem  2 , Derek Byers  2 , Chad Witt  2 , Armin Ghobadi  1 , John F DiPersio  1 , Iskra Pusic  1
Affiliations
Free article
Case Reports

The use of ruxolitinib for acute graft-versus-host disease developing after solid organ transplantation

Miriam T Jacobs et al. Am J Transplant. 2020 Feb.
Free article

Abstract

Development of graft-versus-host disease (GvHD) is a rare complication after transfusions or solid organ transplantation. Patients typically present with a skin rash, diarrhea, liver failure, and bone marrow aplasia. A diagnosis of transfusion/transplantation associated-GvHD is made based on the clinical and histologic evidence, yet it is often delayed due to the nonspecific symptoms attributed to the patient's underlying illness. Several therapeutic approaches are being used including both increasing and withdrawing immunosuppression, and the use of cellular therapies. Unfortunately, the success rate of these approaches is low and the mortality of this complication is very high. New approaches are needed. We report on three cases of GvHD developing after solid organ transplantation treated with ruxolitinib.

Keywords: clinical research/practice; graft-versus-host disease (GVHD); hematology/oncology; immunosuppressant - other; immunosuppression/immune modulation; organ transplantation in general.

PubMed Disclaimer

References

REFERENCES

    1. Gulbahce HE, Brown CA, Wick M, Segall M, Jessurun J. Graft-vs-host disease after solid organ transplant. Am J Clin Pathol. 2003;119(4):568-573.
    1. Shivdasani RA, Haluska FG, Dock NL, Dover JS, Kineke EJ, Anderson KC. Brief report: graft-versus-host disease associated with transfusion of blood from unrelated HLA-homozygous donors. N Engl J Med. 1993;328(11):766-770.
    1. Sharma A, Armstrong AE, Posner MP, et al. Graft-versus-host disease after solid organ transplantation: a single center experience and review of literature. Ann Transplant. 2012;17(4):133-139.
    1. Zhang Y, Ruiz P. Solid organ transplant-associated acute graft-versus-host disease. Arch Pathol Lab Med. 2010;134(8):1220-1224.
    1. Rogulj IM, Deeg J, Lee SJ. Acute graft versus host disease after orthotopic liver transplantation. J Hematol Oncol. 2012;5:50.

Publication types

LinkOut - more resources